adjust dilut earn per share ep defin report
relat cost discontinu oper certain signific
sale forecast although line consensu ep beat reflect much
lower tr ep guidanc estim driven lower tr rest guidanc line
ep estim consensu newli
issu guidanc call ep rais ep
estim tent rais flat
sale forecast
consensu product ahead forecast includ lipitor prevnar
eliqui celebrex xeljanz xtandi
norvasc viagra premarin chantix combin higher product
forecast includ ibranc light eu adjust lyrica
sutent enbrel zyvox xalkori inlyta combin light
revenu guidanc last publish revenu estim
gpm estim sg
forecast estim net
non-oper incom estim tax rate
well forecast ad ep share count
estim
 guidanc cog revenu vs prior last publish
sg spend vs vs net
approxim incom vs tax rate approxim vs
bavencio avelumab ph data ovarian nsclc ph data combo w/
file nsclc ibranc ph ii data pallet neoadjuv bc xeljanz
ph extens data uc approv uc adcom pdufa jun eu
file uc lorlatinib file alk nsclc biosimilar herceptin /eu
approv bsufa apr dacomitinib file egfr nsclc bosulif eu approv
ph cml xtandi full ph data prosper non-metastat cprc gu feb
 approv file sutent eu approv adjuv rcc talazoparib parp
file mbrca bc steglatro ertugliflozin w/mrk eu approv posit
chmp tanezumab w/lli ph data oa clbp pain rivipansel ph data sickl
cell tafamidi ph data cardiomyopathi domagrozumab ph data duchenn
consum divis decis futur statu
pleas see page report import disclosur
outperform rate stock key averag bottom-lin growth
improv innovation/new product flow solid dividend yield
compel valuat share appear under-valued sotp basi
bavencio file lung gastric
xeljanz approv uc march
decis consum busi futur
everi earli stage product
launch achiev
ibranc palbociclib adopt even
brisk expect
pipelin achiev greater expect
accret potenti break-up
compani lead greater valuat
pfizer inc global biopharmaceut compani divers portfolio pharma product
cover area cardiovascular anti-infect anti-inflammatori oncolog
metabol diseas other also strong vaccin portfolio consum product
segment array brand product
cowen compani
chgpfizer innov essenti expens inc mm cowen
cowen compani
cowen compani
chgnet income/exp cowen
cowen compani
chgnet income/exp cowen
cowen compani
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ success pipelin product patent expir greater
expect impact ep success streamlin and/or separ busi
structur outcom potenti
